CD19 CAR-NK cell therapy with rituximab achieved durable complete responses in Waldenström Non-Hodgkin lymphoma, with up to 15 months of remission. The QUILT-106 study reported 100% disease control ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
GC Cell announced on the 27th that it presented interim Phase 1 clinical trial results for its allogeneic umbilical cord ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...
Several patients with acute myeloid leukemia (AML) who were treated with SENTI-202, a chimeric antigen receptor natural killer (CAR-NK) therapy, experienced complete remission after not responding to ...
Subscribe to our newsletter for the latest sci-tech news updates. The study, published in Cancer Cell, opens new avenues for discovering approaches to enhance the antitumor activity of chimeric ...
SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings, has entered into a licensing agreement with Monarch Therapeutics to develop and commercialize its Snap-Car NK cell therapy platform for ...
Hosted on MSN
Scientists discover 'natural cancer killer' is 'safer and more effective' than standard treatment
Top experts have developed new 'natural killer' cells to fight off cancer and lower the risk of disastrous immune effects. Researchers at Harvard Medical School and the Massachusetts Institute of ...
CHICAGO – Several patients with acute myeloid leukemia (AML), who were treated with SENTI-202, a first-in-class chimeric antigen receptor natural killer (CAR NK) cell therapy, experienced a complete ...
Avalon GloboCare secures a patent in Hong Kong for CAR-T and CAR-NK cell technology, enhancing its global intellectual property portfolio. Avalon GloboCare Corp. announced that it has been granted a ...
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results